• Medicine
  • 22 July
  • FDA to approve Sanofi's Subcutaneous Sarclisa
    2
  • FDA to approves Elevar Therapeutics' Rivoceranib + camrelizumab
    2
  • 28 July
  • FDA approves Outlook Therapeutics' ONS-5010
    2
  • 30 July
  • FDA to approves Viatris' low-dose estrogen weekly patch
    2
  • 31 July
  • Measles cases in U.S. by July 31
    6
  • 30 December
  • CDC to issue Level 4 warning by December 31
    2
  • FDA approves Retatrutide this year
    2
  • FDA to approve Daraxonrasib this year
    2